1. Home
  2. SLS vs VOXR Comparison

SLS vs VOXR Comparison

Compare SLS & VOXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLS
  • VOXR
  • Stock Information
  • Founded
  • SLS 2012
  • VOXR 2014
  • Country
  • SLS United States
  • VOXR United States
  • Employees
  • SLS N/A
  • VOXR N/A
  • Industry
  • SLS Biotechnology: Pharmaceutical Preparations
  • VOXR Precious Metals
  • Sector
  • SLS Health Care
  • VOXR Basic Materials
  • Exchange
  • SLS Nasdaq
  • VOXR Nasdaq
  • Market Cap
  • SLS 185.3M
  • VOXR 172.5M
  • IPO Year
  • SLS N/A
  • VOXR N/A
  • Fundamental
  • Price
  • SLS $1.85
  • VOXR $3.53
  • Analyst Decision
  • SLS Strong Buy
  • VOXR
  • Analyst Count
  • SLS 1
  • VOXR 0
  • Target Price
  • SLS $7.00
  • VOXR N/A
  • AVG Volume (30 Days)
  • SLS 1.9M
  • VOXR 298.9K
  • Earning Date
  • SLS 11-12-2025
  • VOXR 11-05-2025
  • Dividend Yield
  • SLS N/A
  • VOXR 1.40%
  • EPS Growth
  • SLS N/A
  • VOXR N/A
  • EPS
  • SLS N/A
  • VOXR N/A
  • Revenue
  • SLS N/A
  • VOXR $10,771,473.00
  • Revenue This Year
  • SLS N/A
  • VOXR $22.51
  • Revenue Next Year
  • SLS N/A
  • VOXR $10.60
  • P/E Ratio
  • SLS N/A
  • VOXR N/A
  • Revenue Growth
  • SLS N/A
  • VOXR N/A
  • 52 Week Low
  • SLS $0.77
  • VOXR $2.21
  • 52 Week High
  • SLS $2.27
  • VOXR $3.79
  • Technical
  • Relative Strength Index (RSI)
  • SLS 52.67
  • VOXR 54.09
  • Support Level
  • SLS $1.69
  • VOXR $3.45
  • Resistance Level
  • SLS $2.01
  • VOXR $3.61
  • Average True Range (ATR)
  • SLS 0.11
  • VOXR 0.13
  • MACD
  • SLS 0.00
  • VOXR -0.01
  • Stochastic Oscillator
  • SLS 50.00
  • VOXR 43.90

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

About VOXR Vox Royalty Corp.

Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.

Share on Social Networks: